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Determination of fetal chromosome
aberrations from fetal DNA in
maternal blood: has the challenge
finally been met?
Sinuhe Hahn1,*, Olav Lapaire2, Sevgi Tercanli2, Varaprasad Kolla1
and Irene Hösli2
The analysis of cell-free fetal nucleic acids in maternal blood for prenatal
diagnosis has been transformed by several recent profound technology
developments. The most noteworthy of these are ‘digital PCR’ and ‘next-
generation sequencing’ (NGS), which might finally deliver the long-sought goal
of noninvasive detection of fetal aneuploidy. Recent data, however, indicate
that NGS might even be able to offer a much more detailed appraisal of the
fetal genome, including paternal and maternal inheritance of point mutations
for mendelian disorders such as β-thalassaemia. Although these
developments are very exciting, in their current form they are still too complex
and costly, and will need to be simplified considerably for their optimal
translation to the clinic. In this regard, targeted NGS does appear to be a step
in the right direction, although this should be seen in the context of ongoing
progress with the isolation of fetal cells and with proteomic screening markers.
In the past few years it has become clear that
the demographic shift towards increasing
maternal age for pregnancies in developed
nations, with its associated risks of fetal
chromosomal anomalies, will necessitate a
change in current strategies for prenatal
screening and detection of fetal aneuploidies
(Refs 1, 2, 3, 4). This is illustrated by a recent
analysis of the English and Welsh National
Down Syndrome (DS) Cytogenetic Register over
the period 1989–2008 (Ref. 5), which reported a
71% increase in the number of diagnosed cases
with DS, with no comparable increase in birth
rate. The increase in the number of cases
with DS was largely attributed to the
concomitant increase in maternal age, as more
than 20% of pregnancies now occur in mothers
older than 35 years (Ref. 5).
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This development is likely to add additional
costs to already strained healthcare budgets,
because positive cases from initial noninvasive
screening based on ultrascans and maternal
serum biochemical analysis need to be verified
by invasive analysis such as amniocentesis or
chorionic villous sampling, which are labour-
intensive examinations requiring highly skilled
personnel (Ref. 6). To break this spiralling cost,
it would be advantageous for any future
noninvasive method to be so accurate that it
could function as a ‘stand-alone’ test and not
require further invasive verification. Naturally, it
will also need to be considerably cheaper than
current invasive practices. An alternative
scenario might be to use such a noninvasive test
to reduce the cost and risk associated with the
invasive analysis of the high number of false-
positive cases resulting from current screening
practice (Refs 7, 8). In either case, strenuous
efforts will need to be undertaken in order to
ensure that cost-effective noninvasive prenatal
diagnosis of DS cases finally becomes a reality
(Ref. 8).
Has research in the field of noninvasive
prenatal diagnosis become ‘mature’?
Since thediscoveryof fetal cell-freeDNA (cf-DNA)
inmaternal plasma or serum in 1997 (Ref. 9), more
than 1000 papers have been published on this
topic. A cursory review of publications listed in
public depositories such as PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) suggests that
the most prolific period was probably the latter
half of the previous decade. In this period,
several large-scale studies were initiated to test
the efficacy of this new-found tool for the
noninvasive determination of fetal genetic traits
such as the fetal RhD (Rhesus D) gene or gender
(Refs 10, 11, 12, 13). These data indicated that
this approach was indeed sufficiently robust that
widespread clinical application could be safely
implemented, and as a result concerted efforts
were undertaken by multicentre consortia, such
as the European Union (EU)-funded SAFE
Network, to standardise these assays (Refs 11,
14). These data also indicated that the analysis
of cf-fetal DNA could form the secure and
sound basis for subsequent developments, such
as the noninvasive detection of fetal
aneuploidies (Ref. 15).
In recent years this prolific output in
publications seems to have largely tapered off,
although the number of reviews dealing with
the field has increased tremendously. Hence the
scenario appears very similar to economic
models of the ‘product life cycle’, where a
particular item has progressed through
development, introduction and growth, and is
settling into a pattern of maturity and
subsequent decline (Ref. 16). Although this
simplistic view might lead to the impression
that research in this field has waned, this is far
from the truth, for this punctuated modicum in
published reports indicates that the field has
finally entered a phase where quality, using a
quantum leap in technological development,
rather than quantity is the prevailing trend. This
facet will become very evident in this review.
The question of fetal cell-free DNA
fragment size and concentration
It is necessary to reiterate that the major problem
still hampering the use of fetal cf-DNA for the
noninvasive detection of fetal genetic loci that
are not distinct from maternal loci is that fetal
sequences constitute only 5–10% of the total cf-
DNA in maternal plasma, and even less in
maternal serum (Refs 17, 18, 19).
Groundbreaking research performed in the
middle of the past decade on the biophysical
properties of cf-DNA indicated that fetal cf-
DNA was more fragmented and had a shorter
size than comparable maternal cf-DNA
fragments (Refs 20, 21). Interestingly, this topic
still continues to be the focus of intense research
efforts and considerable debate (Refs 22, 23, 24).
The fragmentation was exploited for the
selective enrichment of fetal cf-DNA sequences
(to up to 50% of total cf-DNA), thereby
permitting the detection of otherwise masked
fetal genetic loci such as short tandem repeats,
single-nucleotide polymorphisms (SNPs) and
paternally inherited point mutations, such as
those involved in β-thalassaemia or
achondroplasia (Refs 21, 25, 26, 27, 28). These
experiments, however, used conventional
agarose gel electrophoresis for the physical-size-
based separation of fetal and maternal cf-DNA
species – a cumbersome, labour-intensive,
inefficient procedure that is prone to
contamination. For the widespread applicability
of this approach in the clinic, new approaches
such as microfluidics will be required.
Another key development during this period
was verification of the long-standing suspicion
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that fetal cf-DNAwas of placental origin, and was
not the result of the demise of trafficking fetal cells.
This was confirmed by a number of different
approaches, such as analysis of (1) placental
mosaicism, where key fetal loci such as the Y
chromosome were missing both in the placenta
and in fetal cf-DNA, but not in the male fetal
karyotype (Ref. 29), (2) molar pregnancies,
where cf-DNA specific for the molar karyotype
(46 XY) could be detected (Ref. 30), and (3)
epigenetic markers specific for placental tissues,
such as the hypomethylated maspin (SERPINB5)
or the hypermethylated RASSF1 genetic loci
(Refs 31, 32, 33).
The latter markers could prove to be useful as
gender-independent tools to verify the presence
of fetal cf-DNA in ambiguous diagnostic cases,
such as when determining fetal gender or RhD
status (Ref. 10). It might also be possible to use
these as tools to quantify fetal cf-DNA levels
(Ref. 34). Reliable, accurate assessment of fetal
cf-DNA levels, however, appears to require the
use of high-copy sequences, such as DYS14 on
the Y chromosome (Ref. 18).
Indirect methods for the noninvasive
detection of fetal aneuploidy using
cell-free nucleic acids
Allelic transcript ratios
The first indication that cell-free fetal nucleic acids
could be used for the noninvasive prenatal
detection of DS, in 2007, came from an indirect
approach in which chromosomal dosage was
inferred from allelic gene transcript copy
numbers (Ref. 35). The study focused on the
gene PLAC4 (placenta-specific 4), located on
chromosome 21, which was specifically
transcribed in the placenta but not in any
maternal tissues. In this manner, the analysis of
this gene product would be similar to that of the
Y chromosome, in that it would not be hindered
by maternal background. To assess the dosage
of each allelic transcript, heterozygous SNP loci
were used. These could then be quantitatively
assessed using mass spectrometry. In the
analysis of samples from 10 DS cases and 56
healthy controls, DS cases could be detected
with a sensitivity of 90% and a specificity of 96.5%.
However, a serious caveat of this approach is
that the SNP in PLAC4 needs to be
heterozygous in order to derive a conclusion
concerning chromosomal dosage. Hence, a very
large number of cases had to be excluded from
the study, because they failed to meet this
important criterion. Furthermore, the approach
makes a fundamental assumption concerning
the underlying biology for it to work
effectively – namely, that the interrogated alleles
are transcribed at exactly the same rate. This
might not be the case in many instances
(Refs 36, 37), which would make subsequent
analysis unreliable.
Although this RNA-based approach was
subsequently explored by Sequenom, Inc., USA,
it appears not to have been successful.
Unfortunately, details of this study have not
been divulged; it would have been interesting to
determine the cause for its apparent failure,
which perhaps could have been rectified in
subsequent studies.
Epigenetic allelic ratios
A second indirect approach, which was explored
around the same time, involved epigenetic
differences of methylation to distinguish
placental (fetal) genetic loci from maternal loci
(Refs 31, 32, 38, 39, 40). The first report, on the
maspin gene on chromosome 18 (Ref. 38), again
used heterozygous SNP alleles to determine
chromosomal dosage; in this study, however, no
clear distinction could be discerned between
cases with trisomy 18 and unaffected healthy
controls, even when using ‘pure’ fetal and
maternal genetic material, such as fetal material
obtained by amniocentesis. Subsequently,
however, the epigenetic approach has been
explored successfully for cases with trisomy 21
and trisomy 18 (Edwards syndrome; ES)
(Refs 39, 40). In these recent studies much more
encouraging results were obtained, in that all
five DS cases and eight out of nine cases with
ES were correctly identified by the analysis of
epigenetic markers in plasma DNA. The efficacy
of these assays might be improved by the
inclusion of further candidate epigenetic
biomarkers (Refs 39, 40).
In a very recent report, it has been demonstrated
that the enrichment of fetal cf-DNA fragments by
methylated DNA immunoprecipitation can be
used for the successful determination of
chromosome 21 ploidy (Ref. 41). In this study,
hypermethylated fetal cf-DNA fragments,
identified in a previous study (Ref. 42), were
enriched by immunoprecipitation and then
examined by conventional real-time quantitative
polymerase chain reaction (PCR). The fetal-
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specific DNA methylation ratio for each sample
was then calculated by comparing the sample
CT (cycle threshold) value with the median CT
value of a pool of normal control cases. In those
cases where the fetus had a normal karyotype
this ratio was determined to be of the order
of 1, whereas in cases with trisomy 21 this ratio
was larger than 1. To increase the accuracy of
this system, eight methylated genetic regions on
chromosome 21 were examined in parallel. In
a blinded analysis, 14 cases with trisomy 21
could be correctly distinguished from 26
normal cases. The advantage of this system is that
it does not require any specialised equipment, and
can readily be performed by the instruments
currently present in most routine diagnostic
laboratories.
Digital PCR: first hint at direct noninvasive
aneuploidy detection
Most of the studies examining fetal cf-DNA to date
have used a form of real-time PCR and Y-
chromosome-specific sequences (Refs 17, 43).
These studies indicated that the amount of
fetal cf-DNA increases during gestation, and
disappears rapidly from the maternal circulation
following delivery. Increases were also observed
in several pregnancy-related disorders or
conditions such as preeclampsia, preterm
delivery and trisomy 21, suggesting that this
phenomenon could serve as the basis for a new
generation of screening tests.
During this period, studies had indicated that
real-time PCR could be used for the rapid
determination of chromosomal ploidy on pure
fetal genetic material obtained by invasive
means (Ref. 44). Because real-time PCR is not
well suited for the detection of less than twofold
differences in template copy numbers, special
conditions had to be introduced to detect the
1.5-fold difference in template concentration
occurring in trisomy 21. It was, however, very
clear that this approach would not be suited for
the noninvasive determination of DS, because of
the overwhelming presence of maternal cf-DNA
fragments.
Consequently, a different tack had to be taken,
which was provided by ‘digital PCR’ (Ref. 45)
and the advent of microfluidic devices (Ref. 46).
Unlike real-time PCR, where an ‘analogue’
signal of the entire PCR reaction containing the
entire input template is obtained, in ‘digital
PCR’ the PCR reaction is split into thousands of
minute individual reactions, with each
individual reaction containing at most a single
template copy. A quantitative assessment of the
concentration of input template in the sample
examined is then made by counting the number
of individual positive PCR reactions (Fig. 1).
This procedure has been demonstrated to
permit a much more accurate quantification
than more conventional approaches such as real-
time PCR, but, more importantly, it permits the
detection of very small changes in input DNA.
Thus, ‘digital PCR’ could perhaps indicate
whether a fetus was affected by DS, simply by
counting the number of chromosome-21-specific
target sequences in comparison to a similar
locus on an unaffected chromosome (Refs 46, 47,
48, 49) (Fig. 1).
A strategy in which the amyloid gene locus on
chromosome 21 and the GAPDH (glyceraldehyde
3-phosphate dehydrogenase) gene locus on
chromosome 12 were co-examined by digital
PCR was shown to be able to detect DS when
examining pure fetal genetic material obtained
by invasive means (Ref. 47) (Fig. 1). The report
indicated that the method might also be suitable
for the analysis of cf-DNA, in that ‘DS cases’
could be detected using artificial mixtures
involving only 10% DS material, which is very
similar to the concentration of fetal cf-DNA in
maternal plasma. A crucial limitation of these
observations, however, was that they would
hold true only when 10 000 or more individual
PCR reactions were monitored.
Next-generation sequencing and the
possible advent of noninvasive DS
detection
Although reports from two research groups
indicated that digital PCR might offer success
for the noninvasive detection of DS by the
analysis of cf-DNA (Refs 47, 48, 49), these
studies also made it clear that these analyses
would be conducted at the limits of current
digital PCR platforms, which at the time offered
some 12 000 individual reaction events. Hence, if
this strategy were to be pursued, then its
successful transition would require an even
greater level of ‘individual event analysis’ to
permit the necessary degree of discrimination
between normal and DS cases.
This was offered by the advent of ‘next-
generation sequencing (NGS)’, also termed
‘deep sequencing’, whereby the entire genomic
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template is fragmented, sequenced in short reads
and then reassembled through complex
bioinformatic comparison with a genomic
database (Ref. 50). In this manner, subtle
mutations having key roles in tumour initiation
and progression could be ascertained (Refs 51, 52).
Apart from offering unprecedented detail with
regard to genomic alterations, the NGS approach
also offered a unique opportunity to overcome the
current limitation of digital PCR, by providing
information concerning tens of thousands of
sequence reads per chromosome; more than
60 000 reads might be recorded for chromosome
21, and many millions over the entire genome.
In the case of a DS fetus, there would be a small
increase in the number of chromosome 21 reads,
whereas there should not be any comparable
alteration across the other chomosomes. As
such, in a manner akin to digital PCR, by
simply counting the number of chromosome
21 reads, and then comparing these to a much
larger number of sequence reads over the entire
genome, it should be possible to determine the
ploidy of chromosome 21 (Fig. 2). This indeed
was the case, and it was clearly demonstrated
that even minute quantitative alterations in the
number of chromosome 21 reads could lead
to an unparalleled discrimination between
pregnancies bearing a fetus with trisomy 21 or
those with a normal karyotype (Refs 53, 55).
Furthermore, because this analysis was not
restricted to chromosome 21, it was also possible
to detect two cases with ES (trisomy 18) and one
case with Patau syndrome (trisomy 13), thereby
indicating the possible widespread applicability
of this technology (Ref. 55).
The downside of this approach is the
prohibitively high cost per sample and the
length of time taken for sample preparation,
sequencing and subsequent bioinformatic
analysis, which occupies the better part of
several days per sample (Ref. 56).
Is NGS ready for clinical application?
Neverthless, two very recent publications have
suggested that the NGS approach might be
ready to make the transition from the research
laboratory to clinical routine (Refs 7, 8, 34). In
the first of these studies, 753 pregnant women at
risk of having a fetus affected by DS, and who
were therefore about to undergo an invasive
prenatal diagnostic procedure, were recruited
Ratio 21:12 = 1.0 Ratio 21:12 = 1.5
Euploid fetus Aneuploid fetus
PCR for chromosomes 12 and 21
Digital PCR readout
Chromosomal 
complement
12:12
21:21
12:12
21:21:21
Detection of fetal aneuploidy using digital PCR
Expert Reviews in Molecular Medicine © 2011 Cambridge University Press
Figure 1. Detection of fetal aneuploidy using digital PCR. In this procedure, fluorescent PCR specific for
sequences on chromosomes 12 and 21 is carried out in individual microreaction chambers. The amount of
input template is titrated in such a fashion that each microreaction vessel contains >1 copy. After the
plateau phase has been reached (approximately 40 cycles), the PCR reaction is terminated, and the number
of positive reactions for each locus is counted. In euploid cases the ratio of blue (chromosome 12) to red
(chromosome 21) signals should be 1, whereas in cases with Down syndrome the ratio of blue
(chromosome 12) to red (chromosome 21) signals should be 1.5 (illustrated in more detail in Ref. 46). This
method has to date not been successfully used for the detection of fetal aneuploidy using cell-free DNA in
maternal plasma.
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Cell-free
DNA in plasma
Isolate cell-free DNA fragments and prepare library
Examine by next-generation sequencing
ATG, TTA,
CAT,  ATT,
TCA, TAG
Enumerate sequences/chromosome
Compare with reference sample pool to determine ploidy
1 2 3 4 5
1C 2 3 4
N
Z
Detection of fetal aneuploidy using next-generation sequencing
Expert Reviews in Molecular Medicine © 2011 Cambridge University Press
Figure 2. Detection of fetal aneuploidy using next-generation sequencing. In this procedure the cell-free
DNA fragments in maternal plasma are isolated, and a library with special sequence tags is then made. These
tags permit subsequent multiplex analysis. The library is examined by next-generation sequencing, which
determines the sequence of each and every fragment. By bioinformatic analysis these sequences are
ascribed to chromosomal locations. Following this, the number of sequence reads for each chromosome is
counted. For chromosome 21 this is typically of the order of several thousand reads, which can then be
compared with several million reads spread across the genome. If the fetus is affected by Down syndrome,
then slightly more reads will be recorded for chromosome 21 compared with those from a euploid fetus. By
comparing these data with a bank of reference samples, and by the use of predetermined cut-off
values (Z score), the ploidy of the sample being examined can be determined (described in more detail in
Refs 53, 54).
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(Ref. 7); of these, full karyotyping determined
that 86 had a fetus affected by DS. To reduce the
complexity and cost of the NGS analysis, a
multiplex approach was tested, whereby eight
samples were examined in parallel (8-plex). This
was compared with a more costly duplex
analysis on 314 samples (two samples examined
simultaneously). The 8-plex analysis yielded a
sensitivity of 79.1% and a specificity of 98.9%,
whereas the duplex assay yielded 100%
sensitivity and 97.9% specificity (Ref. 7). To
make the assay more efficient, a cohort of
normal samples was used as a standard,
permitting a threshold cut-off value (termed Z)
to be determined: values above this were
deemed to show DS cases (Fig. 2).
Although it is unfortunate that the duplex
analysis was determined to be superior to the
less complex 8-plex analysis, it is not entirely
surprising, in that for the 8-plex assay only
approximately 300 000 total reads were recorded
per sample. This translates to a small fraction of
the billions of reads required to access the entire
genome, and furthermore implies that perhaps
less than 10 000 chromosome-21-specific reads
were recorded. Because the NGS assay, like its
digital PCR predecessor, relies simply on the
counting of individual events, it would seem
that here simply too few single events were
being interrogated.
In the second, independent study, 449 samples
were examined by a more detailed and robust
pair-end 4-plex NGS procedure in which
approximately 5 million reads per sample were
obtained (Ref. 34). In this examination all 39
cases with DS were correctly identified,
although one normal case was incorrectly
classified as DS, thereby yielding 100%
sensitivity and 99.7% specificity. An important
quality control in this study is that the
concentration of fetal cf-DNA was monitored,
and samples with less than 3.9% were excluded
(Ref. 34).
Even if the NGS assays are considered not to be
100% effective, and could not be used as a stand-
alone diagnostic test for DS, it has been suggested
that their use as a secondary-tier screen of high-
risk cases could lead to a 98% reduction in the
number of invasive procedures (Ref. 7). As such,
this avenue certainly does appear to be an
attractive route to pursue (Ref. 8). Accordingly,
large-scale clinical studies are being launched in
Europe and elsewhere.
Can NGS be simplified?
The above results have indicated that the use of
complex cutting-edge genomic tools such as
NGS can finally offer the long-sought dream of
noninvasive detection of fetal aneuploidy
(Refs 1, 56). However, this comes at a very high
cost and unacceptably long analysis. A possible
strategy to overcome these disadvantages is the
targeting of only those chromosomes or regions
of interest such as those on chromosome 21 for
the detection of DS cases. Although several
different strategies exist that permit some form
of target enrichment prior to the subsequent
sequencing step, they have to date been limited
to examination of intact genomic DNA samples,
and not fragmented DNA species such as those
found in cf-DNA (Ref. 57). Furthermore, these
procedures, such as on-array capture, require
rather large concentrations of input template
DNA (up to 7.5 μg per sample). Hence, an
approach that permitted targeted sequencing of
the small quantities of fragmented DNA in
maternal plasma had to be sought.
Very recently, a solution hybrid selection
method using ultralong oligonucleotides,
commercially marketed by Agilent, USA, has
been used for targeted enrichment (Ref. 57)
(Fig. 3). A capture library specific for the X
chromosome was hybridised with 500 ng of an
amplified plasma DNA library, and the selected
capture targets were pulled down using a
combination of biotinylated oligonucleotide
probes and streptavidin-coated magnetic beads.
The enriched target DNA was then subjected to
a further 12 rounds of PCR with specially
tagged primers necessary for the subsequent
sequence analysis. In the examination of 12
maternal plasma samples, this targeted capture
procedure led to a mean enrichment of 213-fold.
This enrichment was also reflected in the
increased ability to detect fetal-specific loci on
the X chromosome, which changed from 3.5% in
the un-enriched samples to 95.9% in the samples
subjected to a targeted enrichment step.
A concernwith any enrichment approach is that
it might lead to bias, by preferential enhancement
of select sequences, including the preferential
accumulation of maternal cf-DNA sequences
over fetal ones. However, in this study the
proportion of fetal to maternal sequences was
similar in un-enriched loci (∼16–30% from
first to third trimester) and in enriched X-
chromosome regions (∼15–32%) (Ref. 57). These
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results are encouraging, because they could
facilitate targeted enrichment of more crucial
fetal loci, such as those on chromosome 21,
thereby paving the way for a less complex
noninvasive test for DS.
How much information is available from
NGS?
The first series of experiments with NGS focused
on select chromosomes and compared the number
of readsobtained for these to those obtained for the
entire genomic complement. Because close to
65 000 individual loci are counted on
chromosome 21 alone, it was open to debate
whether this approach would be sufficiently
sensitive to detect more subtle chromosomal
aberrations such as the Robertsonian
translocation between chromosomes 21 and 15
(or 14), which has a role in 2–3% of cases with
DS (Ref. 1). As the Down Syndrome Critical
Region associated with this translocation is a
lot smaller than the entire chromosome 21
commonly involved in DS, it was unclear
whether the NGS approach would be able to
detect this alteration (Ref. 1).
However, this view has been altered by a new
landmark publication, in which the entire cf-
DNA present in a maternal plasma sample was
sequenced (Ref. 24). The data indicated that the
entire fetal genome complement is present in
cf-DNA in maternal plasma, and that this can be
mined to show minute details such as mutations
Cell-free
DNA
Isolate cell-free DNA fragments
and prepare library
Hybridise to SureSelectTM
Oligo Capture Library
Select bound DNA fragments
Examine by next-generation
sequencing
ATG, TTA,
CAT,  ATT,
TCA, TAG
Schematic representation of a 
targeted sequencing approach using 
the SureSelectTM Target Enrichment 
System
Expert Reviews in Molecular Medicine
© 2011 Cambridge University Press
Figure 3. Schematic representation of a targeted
sequencing approach using the SureSelectTM
Target Enrichment System.
Figure 3. Schematic representation of a targeted
sequencing approach using the SureSelectTM
Target Enrichment System. In this procedure the
cell-free DNA fragments are isolated and a library
is generated as per the standard next-generation
sequencing protocol. Prior to sequencing,
however, this library is hybridised to the
SureSelectTM Oligo Capture Library, which is
manufactured in such a manner that it will
recognise a specific chromosome, such as
chromosome 21. These oligo sequences contain
magnetic particles to permit their retrieval in a
magnetic field. Hence, following hybridisation
(65°C, 24 h), captured sequences are selected by
magnetic selection, and unselected sequences are
washed away. The bound fragments are then
purified and prepared for sequencing and
examined as described for Figure 2. This
procedure was recently shown to permit a 213-fold
enrichment of the targeted X chromosome (Ref. 57).
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involved inβ-thalassaemia; surprisingly, the study
correctly discerned that the fetus had inherited the
paternal codon 41/42 mutation, involving a CTTT
deletion, but not thematernal−28A→Gmutation.
Although this analysis was very complex,
involving almost 4 billion reads and 900 000
SNPs, it is a striking indicator of what might lie
ahead – namely, the ability to obtain a full fetal
karyotype down to miniscule single-nucleotide
detail from a single maternal blood sample
(Ref. 24).
The question of intellectual property and
how to optimise procedures
An important concern that needs to be
addressed is how intellectual property and
commercialisation will affect future research and
applications (Ref. 58). For the best possible
service to reach the patient, clarity is essential;
otherwise, conflicting reports and views might
prevent superior products from being
developed. In the case of fetal cf-DNA, such an
issue was raised by the commercialisation of a
noninvasive test for fetal RhD determination in
the EU, and subsequently in the USA (Ref. 58).
Although it was clear to leading researchers in
the field that the tests initially marketed might
be flawed or were not state of the art, it was felt
that it would be a weary process to convince the
commercial parties involved to change their
standard of practice and to adopt more modern
effective approaches. This issue was further
highlighted by the near-simultaneous reports
concerning the application of digital PCR or
NGS, leading to conflicting reports in the lay
media as to who the main patent claimants were
(Refs 1, 59). It is currently also unclear what
business model or strategies should be used in
translating this research from the bench to the
clinic. Hence, it might be worthwhile to echo
previous concerns that such uncertainty might
hinder or restrict further research in the field
(Ref. 60).
Are fetal cells in maternal blood still
worth pursuing?
Despite the enormous strides that have beenmade
with the determination of fetal aneuploidies
through the use of cf-DNA, the latest reports
have indicated that these will be very labour
intensive, and require extremely high-tech
devices and bioinformatic services. Hence it is
unclear how quickly these developments will be
translatable into the clinic.
For this reason there has been a resurgent
interest in the isolation of fetal cells from
maternal blood. This have been fostered by
the development of (1) sophisticated high-
throughput automated scanning devices, which
permit the rapid identification of putative target
fetal cells among a large pool of maternal cells
(Refs 61, 62), and (2) efficient microfluidic
systems and electronic micromanipulation
systems, which permit the effective retrieval of
individual trafficking fetal cells (Refs 59, 63, 64).
Even though this processwill most likelyalso be
laborious, it has several advantages over cf-DNA
analysis, in that fetal cells offer a pure source of
fetal genomic material. Furthermore, widely
standardised procedures commonly used in
many diagnostic laboratories, such as FISH
(fluorescence in situ hybridisation), can be
applied for the very rapid detection of
chromosomal anomalies (Ref. 65). In addition,
use can now be made of a wide body of
experience in the analysis of single cells, a
routine practice in many in vitro fertilisation
clinics offering preimplantation genetic
diagnosis (PGD) (Ref. 66).
A possible further advantage is that the
intellectual property situation in this area is not
as complex as that of cf-DNA, in that many of
the original patents are close to expiry, and no
commercial entity holds a wide portfolio of key
elements. As such, it will be of interest to
monitor progress in this sphere of research,
because it might yet have a few surprises in store.
The challenge of proteomics
The development of the first-trimester DS
screening test using a combination of ultrasound
measurement of nuchal translucency, serum
analyte analysis and maternal age has led to a
dramatic increase in the ability to detect
pregnancies at-risk of bearing an aneuploid
fetus (85% sensitivity) when compared with
the previous generation of second-trimester
screening tests (65% sensitivity), which relied
solely on serum analyte analysis in combination
with maternal age (Ref. 67). This facet is
reflected in the report on the English and Welsh
National Down Syndrome Cytogenetic Register
analysis, which indicated that the vast majority
of DS cases were detected by current screening
practice (Ref. 5).
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The downside of this startling development is
that the first-trimester screen is still hampered
by a rather high false-positive rate of 5–8%
(Refs 68, 69). This implies that a large number of
healthy pregnancies are being subjected to
unnecessary invasive procedures – a healthcare
risk for mother and unborn child, as well as a
considerable financial burden for healthcare
services. Furthermore, almost 15% of cases
remain undetected and, because these occur in
the group of pregnant women not judged to be
at a higher risk (<35 years old), could result in
undesired live births.
Therefore, increasing the efficiency of this
test has been proposed, perhaps by the addition
of further biochemical analytes, such as
members of the activin family (Refs 70, 71). The
inclusion of further highly specific blood-based
analytes might be possible as a result of the
development of quantitative proteomic
technologies as part of the Human Proteome
Association, especially the affiliated plasma
proteome project (Ref. 72). The placenta in DS
cases exhibits structural alterations, which are
most likely the result of alterations in protein
expression, and so it is possible that these
changes will be reflected in the maternal plasma
proteome (Ref. 73). In this regard, the use of
quantitative isobaric labelling has been shown to
permit the detection of significant alterations in
the levels of several placenta-derived peptides in
DS cases when compared with controls (Ref. 74).
Analogous observations have been made by
other research groups using a variety of
different proteomic approaches (Refs 75, 76, 77,
78). It now remains to explore how useful these
potential biomarkers will be in increasing the
detection rate of the current first-trimester screen.
Summary and conclusion
Tremendous strides have been made with the
analysis of fetal cf-DNA in maternal blood, in
that we now stand on the threshold of a new
generation of noninvasive diagnostic tools,
which might even permit a detailed analysis of
the entire fetal genome or a full karyotype.
However, it remains to be seen how rapidly
these can be translated into the clinic, in a
manner that is cost effective and accessible to
all. In this context it will be interesting to see
which system, namely NGS, digital PCR
or enrichment of methylated fetal cf-DNA
fragments, passes the final hurdle to enter
clinical service. Although the isolation and
analysis of trafficking fetal cells might remain a
peripheral test, it could be useful in those
centres already offering FISH or PGD services.
Should multiparameter mass spectroscopy and
quantitative proteomics finally come of age, it
might yield a set of biomarkers with
unparalleled specificity, not only for DS
screening but also for other pregnancy-related
disorders such as preeclampsia.
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